Primary results were recently reported at ESMO (European Society of Medical Oncology) Breast Cancer congress 2022: ORR from the combination therapy in the HER2+ cohort was 65.6% (95% CI, 46.8–81.4%), failing to prove its primary endpoint. Here, ERBB2 is linked to breast carcinoma.